NCT02945163View on ClinicalTrials.gov

Dosing of Tenofovir and Efavirenz in Antiretroviral Therapy

PHASE4CompletedINTERVENTIONAL
Enrollment

184

Participants

Timeline

Start Date

March 5, 2018

Primary Completion Date

June 5, 2019

Study Completion Date

August 31, 2019

Conditions
HIV Infections
Interventions
DRUG

Tenofovir

Tenofovir Disoproxil Fumarate

DRUG

Lamivudine

Lamivudine

DRUG

Efavirenz

Efavirenz

Trial Locations (3)

201508

Shanghai Public Health Clinical Center, Shanghai

210003

The Second Hospital of Nanjing, Nanjing

650041

Yunnan provincial infectious disease hosipital, Kunming

All Listed Sponsors
collaborator

The Second Hospital of Nanjing Medical University

OTHER

collaborator

Yunnan Provincial Infectious Disease Hospital

OTHER

lead

Shanghai Public Health Clinical Center

OTHER_GOV

NCT02945163 - Dosing of Tenofovir and Efavirenz in Antiretroviral Therapy | Biotech Hunter | Biotech Hunter